Insilico Medicine: AI Drug Discovery Benchmark Launched

Insilico Medicine has launched the industry's first Drug Discovery and Development Benchmark as a Service. This new service evaluates frontier AI and foundation models using real-world science. Here's the thing: many current AI benchmarks in drug discovery suffer from data contamination. This means models might get high scores by memorizing training data, but then fail in real drug candidate decisions. To address this, Insilico's new service uses decontaminated real-world data and validated programs. It measures how AI models perform on tasks across medicinal chemistry, chemical synthesis, disease biology, clinical development, and longevity research. The service includes two evaluation suites: "Drug Discovery Foundations" and "Drug Candidate Essentials." These suites assess core competencies and a model's ability to navigate an entire drug discovery program. Organizations can have their AI models evaluated by contacting Insilico Medicine. They receive a verified score report comparing their performance to leading models. This matters because it provides a reliable way to test if AI models can truly discover drugs.